- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute | Strategic Alliance Partners
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Latest from Dana-Farber Cancer Institute
Dr. McGregor Compares Recent Data With Combinations in RCC
June 06, 2018
Video
Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, compares recent data with combination therapy in renal cell carcinoma.
Dr. Fraizer Discusses the MaGIC Consortium
May 29, 2018
Video
Lindsay Frazier, MD, institute physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, associate professor of pediatrics, Harvard Medical School, discusses the Malignant Germ Cell International Consortium (MaGIC) in pediatric and rare tumors.
Harvard Expert Sees Potential in BCL-2 Combos
May 27, 2018
Article
Anthony G. Letai, MD, PhD, discusses the complex nature of apoptosis and efforts to target the process.
Dr. McGregor on New Combinations With Immunotherapy in RCC
May 23, 2018
Video
Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses new combinations with immunotherapy in renal cell carcinoma.
Dr. Harshman on Earlier Use of Immunotherapy in RCC
May 18, 2018
Video
Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).
Dr. Choueiri Discusses the Current State of RCC Treatment
May 17, 2018
Video
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the current treatment of patients with renal cell carcinoma.
Stemness Inhibitor Tested in Rare Hematologic Cancer
May 17, 2018
Article
SL-401, a novel therapy that targets a cancer stemness pathway, is being investigated in patients with blastic plasmacytoid dendritic cell neoplasm in a phase I/II trial.
Harshman Addresses Potentially Practice-Changing Adjuvant Therapy Trials in RCC
May 14, 2018
Article
Lauren C. Harshman, MD, discusses ongoing clinical trials examining the incorporation of immune therapies into practice.
Standard of Care Continues to Shift in RCC
May 11, 2018
Article
Toni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.
Dr. Harshman Discusses the Potential for New RCC Treatments
May 10, 2018
Video
Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses the potential for new treatment options in renal cell carcinoma.
Expert Underscores Importance of AE Management in GU Cancers
May 10, 2018
Article
Xiao X. Wei, MD, MAS, discusses managing possible adverse events of different systemic therapies in kidney and bladder cancer.
Sonpavde Navigates the Evolving Bladder Cancer Landscape
May 09, 2018
Article
Guru P. Sonpavde, MD, navigates through the treatment landscape of urothelial carcinoma.
Combinations Take Hold in Kidney Cancer
May 07, 2018
Article
Bradley A. McGregor, MD, discusses the growth of combination therapy in the treatment of patients with kidney cancer.
Dr. Wei on Immune-Related Adverse Events in GU Cancers
April 24, 2018
Video
Xiao X. Wei, MD, MAS, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immune-related adverse events (irAE) in genitourinary (GU) cancers.
Role of PARP Inhibitors in Breast Cancer Continues to Be Refined
April 20, 2018
Article
Nadine M. Tung, MD, discusses the role of PARP inhibitors for patients with BRCA-positive breast cancer and the importance of genetic testing.
Dr. Choueiri Highlights the Latest in Genitourinary Cancer Research
April 12, 2018
Video
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the latest treatments in genitourinary (GU) cancers.
Dr. McGregor on Immunotherapy Combinations in Kidney Cancer
April 07, 2018
Video
Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses combinations of immunotherapy for patients with kidney cancer.
Dr. Harshman on the PROTECT Trial in Patients With Locally Advanced RCC
April 06, 2018
Video
Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses how the PROTECT trial sought to answer the controversial results of the ASSURE and S-TRAC trials.
Dr. Bellmunt on The Cancer Genome Atlas Project in Bladder Cancer
April 05, 2018
Video
Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses The Cancer Genome Atlas (TCGA) project in bladder cancer.
Dr. Wei on the Use of Cabozantinib in Advanced Kidney Cancer
April 05, 2018
Video
Xiao X. Wei, MD, MAS, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the side effect profile of cabozantinib (Cabometyx) in advanced kidney cancer.